Lucid Diagnostics Stock Probability of Future Stock Price Finishing Over 10.50
| LUCD Stock | USD 0.79 0.02 2.60% |
Lucid |
Lucid Diagnostics Target Price Odds to finish over 10.50
The tendency of Lucid Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 10.50 or more in 90 days |
| 0.79 | 90 days | 10.50 | close to zero percent |
Based on a normal probability distribution, the odds of Lucid Diagnostics to move over $ 10.50 or more in 90 days from now is close to zero percent (This Lucid Diagnostics probability density function shows the probability of Lucid Stock to fall within a particular range of prices over 90 days) . Probability of Lucid Diagnostics price to stay between its current price of $ 0.79 and $ 10.50 at the end of the 90-day period is about 84.35 .
Given the investment horizon of 90 days Lucid Diagnostics has a beta of 0.31. This indicates as returns on the market go up, Lucid Diagnostics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Lucid Diagnostics will be expected to be much smaller as well. Additionally Lucid Diagnostics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Lucid Diagnostics Price Density |
| Price |
Predictive Modules for Lucid Diagnostics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Lucid Diagnostics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Lucid Diagnostics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Lucid Diagnostics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Lucid Diagnostics is not an exception. The market had few large corrections towards the Lucid Diagnostics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Lucid Diagnostics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Lucid Diagnostics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.09 | |
β | Beta against Dow Jones | 0.31 | |
σ | Overall volatility | 0.09 | |
Ir | Information ratio | -0.05 |
Lucid Diagnostics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Lucid Diagnostics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Lucid Diagnostics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Lucid Diagnostics generated a negative expected return over the last 90 days | |
| Lucid Diagnostics has some characteristics of a very speculative penny stock | |
| Lucid Diagnostics has high historical volatility and very poor performance | |
| Lucid Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.43 M. Net Loss for the year was (52.67 M) with loss before overhead, payroll, taxes, and interest of (3.24 M). | |
| Lucid Diagnostics currently holds about 34.46 M in cash with (32.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Lucid Diagnostics has a poor financial position based on the latest SEC disclosures | |
| Roughly 61.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Prospective Clinical Utility Study of Lucid Diagnostics EsoGuard Esophageal DNA Test Accepted for Peer-Reviewed Publication - Marketscreener.com |
Lucid Diagnostics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Lucid Stock often depends not only on the future outlook of the current and potential Lucid Diagnostics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Lucid Diagnostics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 41.8 M | |
| Cash And Short Term Investments | 18.9 M |
Lucid Diagnostics Technical Analysis
Lucid Diagnostics' future price can be derived by breaking down and analyzing its technical indicators over time. Lucid Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Lucid Diagnostics. In general, you should focus on analyzing Lucid Stock price patterns and their correlations with different microeconomic environments and drivers.
Lucid Diagnostics Predictive Forecast Models
Lucid Diagnostics' time-series forecasting models is one of many Lucid Diagnostics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Lucid Diagnostics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Lucid Diagnostics
Checking the ongoing alerts about Lucid Diagnostics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Lucid Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Lucid Diagnostics generated a negative expected return over the last 90 days | |
| Lucid Diagnostics has some characteristics of a very speculative penny stock | |
| Lucid Diagnostics has high historical volatility and very poor performance | |
| Lucid Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.43 M. Net Loss for the year was (52.67 M) with loss before overhead, payroll, taxes, and interest of (3.24 M). | |
| Lucid Diagnostics currently holds about 34.46 M in cash with (32.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Lucid Diagnostics has a poor financial position based on the latest SEC disclosures | |
| Roughly 61.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Prospective Clinical Utility Study of Lucid Diagnostics EsoGuard Esophageal DNA Test Accepted for Peer-Reviewed Publication - Marketscreener.com |
Check out Lucid Diagnostics Backtesting, Lucid Diagnostics Valuation, Lucid Diagnostics Correlation, Lucid Diagnostics Hype Analysis, Lucid Diagnostics Volatility, Lucid Diagnostics History as well as Lucid Diagnostics Performance. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share 0.09 | Quarterly Revenue Growth 0.497 | Return On Assets (1.01) | Return On Equity (10.08) |
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.